Osteoporosis Clinical Trials

Postmenopausal Osteoporosis is the medical term used for the disease that weakens bones in women, increasing the risk of sudden and unexpected fractures. Literally meaning "porous bone," osteoporosis results in an increased loss of bone mass and strength. The disease often progresses without any symptoms or pain. Many times, osteoporosis ...

Currently we have the following studies: Birth Control/ Contraceptive Vaginal Atrophy Pain During Intercourse Dysplasia Endometriosis Pap Smear Mammogram Bone Density Osteoporosis Nocturia Uterine Fibroids Uterine Bleeding Post Menopausal Studies HPV STD Hot Flashes

We are looking for postmenopausal women, 45 years of age or older, who have been diagnosed with osteoporosis to participate in a clinical research study. This study is currently enrolling, and will evaluate the safety and effectiveness of an investigational medication in reducing fractures due to osteoporosis. There is no ...

Currently looking for women who: Are 55 years or older and prescribed a daily or weekly medication for osteoporosis Have stopped using osteoporosis medication, or have not taken osteoporosis medication as prescribed by their doctor Are willing to participate in a 12-month study Your participation in a study could help ...

Osteoporosis is a disease in which bones become thin and weak causing them to break more easily. It is often called a "silent disease" because there are no symptoms; you can't feel your bones becoming weak. You may be at risk if you… Are over 50 years old Are postmenopausal ...

Vitamin D and calcium have been known to function together to maintain skeletal health. Vitamin D is obtained through either skin (via sunlight) or food (certain fish, and mostly from fortified foods like milk, cereal, and juices). It then acts on the body to increase absorption of calcium in the ...

Have you been diagnosed with Osteoporosis?  

To examine the changes of bone mineral density and bone turnover markers after Bonviva treatment in osteoporotic patients

The primary objective of this study is to test the efficacy of a potent anti-resorptive agent, denosumab [receptor activator of nuclear factor-B ligand (RANKL) antibody; Amgen Inc.] to preserve bone mass at the hip and knee and trabecular connectivity at the knee after subacute motor-incomplete SCI [American Spinal Injury Association ...

Osteoporosis in premenopausal women with normal menstrual function and no specific cause is termed idiopathic osteoporosis (IOP). IOP is a rare disease with an estimated prevalence of <200,000 affected premenopausal women in the United States. Women with IOP completing at least one year and up to three years of denosumab ...